Clinical Trial Update: INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure. [Phase 2]

View source ↗

Summary

Phase 2 INNOVE study comparing 3 months of induction with Fuzeon (enfuvirtide) plus optimized background therapy versus optimized background alone in HIV-infect…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Fuzeon (enfuvirtide)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: HIV Infections | Phase 2 | Status: COMPLETED